Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-23

Clinical Trial Update: Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure [Phase 4]

View source ↗

Summary

Phase 4 trial investigating flumazenil for hypoactive delirium due to benzodiazepine exposure; study terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Flumazenil (flumazenil)

Snippet

Sponsor: University of California, Davis | Conditions: Hypoactive Delirium | Phase 4 | Status: TERMINATED | Results posted: 2020-07-23